BioCentury
ARTICLE | Emerging Company Profile

Tyra: designing kinase inhibitors resistant to mutations

Emerging Company Profile: Tyra’s crystal structure generation platform accelerates design of kinase inhibitors resilient to resistance mutations

April 23, 2021 6:10 PM UTC

Tyra is using its platform for rapidly generating X-ray crystal structures to accelerate the design of targeted small molecule kinase inhibitors that aren’t vulnerable to cancer drug resistance mutations.

The company, founded in 2018 by CEO Todd Harris and COO Daniel Bensen and incubated by Alta Partners, has raised $156 million in two financings including a Nextech Invest-led $106 million series B announced in March...

BCIQ Company Profiles

Tyra Biosciences Inc.